Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder

Karaaslan, Zerrin; YILMAZ, VUSLAT; Yüceer, Hande; Şanlı, Elif; AKCAY, halil ibrahim; Türkoğlu, Recai; Tuzun, Erdem; Kürtüncü, Murat

doi:10.14744/nci.2022.77861

Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder

Zerrin KARAASLAN, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Nörobilim Anabilim Dalı, İstanbul, Türkiye)

Vuslat YILMAZ, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Nörobilim Anabilim Dalı, İstanbul, Türkiye)

Hande YÜCEER, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Nörobilim Anabilim Dalı, İstanbul, Türkiye)

Elif ŞANLI, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Nörobilim Anabilim Dalı, İstanbul, Türkiye)

halil ibrahim AKCAY, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Nörobilim Anabilim Dalı, İstanbul, Türkiye)

Murat KÜRTÜNCÜ, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Nöroloji Anabilim Dalı, İstanbul, Türkiye)

Recai TÜRKOĞLU, (Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Nöroloji Bölümü, İstanbul, Türkiye)

Erdem TÜZÜN (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Nörobilim Anabilim Dalı, İstanbul, Türkiye)

İstanbul Kuzey Klinikleri

2 2

Yıl: 2023 Cilt: 10 Sayı: 3 Sayfa Aralığı: 341 - 344 Metin Dili: İngilizce DOI: 10.14744/nci.2022.77861 İndeks Tarihi: 27-07-2023

Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder

Öz:

OBJECTIVE: Our aim was to determine whether serum C-X-C motif chemokine 5 (CXCL5) may serve as a diagnostic biomarker for relapsing-remitting multiple sclerosis (RRMS) as well as a marker that can be used to predict treatment response. METHODS: CXCL5 levels were measured by ELISA in sera of 20 RRMS patients under fingolimod treatment, 10 neuromyelitis optica spectrum disorder (NMOSD) patients, 15 RRMS patients presenting predominantly with spinal cord and optic nerve attacks (MS-SCON), and 14 healthy controls. RESULTS: Fingolimod treatment significantly reduced CXCL5 levels. CXCL5 levels were comparable among NMOSD and MSSCON patients. CONCLUSION: Fingolimod might regulate the innate immune system. Serum CXCL5 measurement does not differentiate between RRMS and NMOSD.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Kostic M, Dzopalic T, Zivanovic S, Zivkovic N, Cvetanovic A, Stojanovic I, et al. IL-17 and glutamate excitotoxicity in the pathogenesis of multiple sclerosis. Scand J Immunol 2014;79:181–6.
2. Chang MS, McNinch J, Basu R, Simonet S. Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene. J Biol Chem 1994;269:25277–82.
3. Rumble JM, Huber AK, Krishnamoorthy G, Srinivasan A, Giles DA, Zhang X, et al. Neutrophil-related factors as biomarkers in EAE and MS. J Exp Med 2015;212:23–35.
4. Carlson T, Kroenke M, Rao P, Lane TE, Segal B. The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J Exp Med 2008;205:811–23.
5. Sheridan GK, Dev KK. S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures. Glia 2012;60:382–92.
6. Yang T, Wang S, Zheng Q, Wang L, Li Q, Wei M, et al. Increased plasma levels of epithelial neutrophil-activating peptide 78/CXCL5 during the remission of Neuromyelitis optica. BMC Neurol 2016;16:96.
7. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177–89.
8. Lepennetier G, Hracsko Z, Unger M, Van Griensven M, Grummel V, Krumbholz M, Berthele A, et al. Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases. J Neuroinflammation 2019;16:219.
9. Thomas K, Sehr T, Proschmann U, Rodriguez-Leal FA, Haase R, Ziemssen T. Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation. J Neuroinflammation 2017;14:41.
10. O’Sullivan SA, O’Sullivan C, Healy LM, Dev KK, Sheridan GK. Sphingosine 1-phosphate receptors regulate TLR4-induced CXCL5 release from astrocytes and microglia. J Neurochem 2018;144:736–47.
11. Pigard N, Elovaara I, Kuusisto H, Paalavuo R, Dastidar P, Zimmermann K, et al. Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression. J Neuroimmunol 2009;209:114–20.

APA	Karaaslan Z, YILMAZ V, Yüceer H, Şanlı E, AKCAY h, Kürtüncü M, Türkoğlu R, Tuzun E (2023). Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder. , 341 - 344. 10.14744/nci.2022.77861
Chicago	Karaaslan Zerrin,YILMAZ VUSLAT,Yüceer Hande,Şanlı Elif,AKCAY halil ibrahim,Kürtüncü Murat,Türkoğlu Recai,Tuzun Erdem Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder. (2023): 341 - 344. 10.14744/nci.2022.77861
MLA	Karaaslan Zerrin,YILMAZ VUSLAT,Yüceer Hande,Şanlı Elif,AKCAY halil ibrahim,Kürtüncü Murat,Türkoğlu Recai,Tuzun Erdem Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder. , 2023, ss.341 - 344. 10.14744/nci.2022.77861
AMA	Karaaslan Z,YILMAZ V,Yüceer H,Şanlı E,AKCAY h,Kürtüncü M,Türkoğlu R,Tuzun E Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder. . 2023; 341 - 344. 10.14744/nci.2022.77861
Vancouver	Karaaslan Z,YILMAZ V,Yüceer H,Şanlı E,AKCAY h,Kürtüncü M,Türkoğlu R,Tuzun E Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder. . 2023; 341 - 344. 10.14744/nci.2022.77861
IEEE	Karaaslan Z,YILMAZ V,Yüceer H,Şanlı E,AKCAY h,Kürtüncü M,Türkoğlu R,Tuzun E "Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder." , ss.341 - 344, 2023. 10.14744/nci.2022.77861
ISNAD	Karaaslan, Zerrin vd. "Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder". (2023), 341-344. https://doi.org/10.14744/nci.2022.77861

APA	Karaaslan Z, YILMAZ V, Yüceer H, Şanlı E, AKCAY h, Kürtüncü M, Türkoğlu R, Tuzun E (2023). Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder. İstanbul Kuzey Klinikleri, 10(3), 341 - 344. 10.14744/nci.2022.77861
Chicago	Karaaslan Zerrin,YILMAZ VUSLAT,Yüceer Hande,Şanlı Elif,AKCAY halil ibrahim,Kürtüncü Murat,Türkoğlu Recai,Tuzun Erdem Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder. İstanbul Kuzey Klinikleri 10, no.3 (2023): 341 - 344. 10.14744/nci.2022.77861
MLA	Karaaslan Zerrin,YILMAZ VUSLAT,Yüceer Hande,Şanlı Elif,AKCAY halil ibrahim,Kürtüncü Murat,Türkoğlu Recai,Tuzun Erdem Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder. İstanbul Kuzey Klinikleri, vol.10, no.3, 2023, ss.341 - 344. 10.14744/nci.2022.77861
AMA	Karaaslan Z,YILMAZ V,Yüceer H,Şanlı E,AKCAY h,Kürtüncü M,Türkoğlu R,Tuzun E Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder. İstanbul Kuzey Klinikleri. 2023; 10(3): 341 - 344. 10.14744/nci.2022.77861
Vancouver	Karaaslan Z,YILMAZ V,Yüceer H,Şanlı E,AKCAY h,Kürtüncü M,Türkoğlu R,Tuzun E Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder. İstanbul Kuzey Klinikleri. 2023; 10(3): 341 - 344. 10.14744/nci.2022.77861
IEEE	Karaaslan Z,YILMAZ V,Yüceer H,Şanlı E,AKCAY h,Kürtüncü M,Türkoğlu R,Tuzun E "Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder." İstanbul Kuzey Klinikleri, 10, ss.341 - 344, 2023. 10.14744/nci.2022.77861
ISNAD	Karaaslan, Zerrin vd. "Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder". İstanbul Kuzey Klinikleri 10/3 (2023), 341-344. https://doi.org/10.14744/nci.2022.77861